The Second COVID-19 Wave: Collateral Impact on Patients of Liver Disease
NCT ID: NCT05167305
Last Updated: 2022-01-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1316 participants
OBSERVATIONAL
2021-12-22
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Monitoring and assessment: Hospital records of all patients of liver disease needing admission during the April-May 2019 and 2021, but without active COVID-19 infection, will be reviewed. Patients will be analyzed and compared for the demographic characteristics, severity of liver disease at time of admission and outcome in form of survival or mortality, liver transplantation rates in the two time periods and 30 d and 90 d readmission rate.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Long Haul COVID-19 and Vaccine Immunogenicity in Patients With Liver Disease
NCT05107271
Impact of the Covid-19 Pandemic on Gastrointestinal and Liver Diseases
NCT04420637
Effect of Lockdown During COVID 19 Pandemic on Liver Disease and Metabolic Parameters.
NCT05028842
An Online Survey to Understand Feelings Related to COVID-19 Among ILBS Patients With Liver Disease
NCT04352491
The Spectrum and Profile of COVID-19 Infection and Its Impact on Liver.
NCT04345640
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
liver disease without COVID-19 infection-April-May 2019
This is an observational study
This is an observational study
liver disease without COVID-19 infection -April- May 2021
This is an observational study
This is an observational study
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
This is an observational study
This is an observational study
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institute of Liver and Biliary Sciences, India
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institute of Liver & Biliary Sciences
New Delhi, National Capital Territory of Delhi, India
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ILBS-COVID-07
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.